



#10/ JRU

Practitioner's Docket No. MWH-303US2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Drysdale, Connie M.; Judson, Richard S.; Liggett, Stephen B.; Nandabalan, Krishnan; and Stephens, J. Claiborne

Application No.: 09/811,285
Filing Date: March 16, 2001

Examiner: Joseph Murphy
Art Unit: 1646

For: Association of Beta2-Adrenergic Receptor Haplotypes with Drug Response

Assistant Commissioner for Patents
Washington, D.C. 20231

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last (37 C.F.R. section 1.97(b)).

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Respectfully submitted,

GENAISSANCE PHARMACEUTICALS, INC.


Date: 11/12/02
Tel. No. 203-786-3473
Registration No. 47,562
g.field@genaisance.com

By: Gisela M. Field
Gisela M. Field



25106

PATENT TRADEMARK OFFICE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1		Complete if Known	
		Application Number	09/811,285
		Filing Date	03/16/2001
		First Named Inventor	Connie M. Drysdale
		Group Art Unit	1646
		Examiner Name	Joseph Murphy
		Attorney Docket Number	MWH-0303US2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BQ	GenBank Accession Number J02960.1 GI:178203. February 13, 1996.	
	BR	GenBank Accession Number AC011334.5 GI:17105283. November 27, 2001.	
	BS	GenBank Accession Number AC116312.2 GI:19774486. November 28, 2002.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.